Characterization of a new human monoclonal antibody directed against the Vel antigen

Danger, Yannic; Danard, S.; Gringoire, Vanessa; Peyrard, Thierry; Riou, Patrice; Sémana, G.; Vérité, Franck

doi:10.1111/vox.12321

Cited by 9 publications

(15 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, generating Vel‐specific hybridoma cell lines based on mouse immunization is likely to be difficult due to the high homology between human and mouse SMIM1 extracellular domain . A Vel‐specific antibody‐producing human hybridoma cell line was recently described, which was also generated from an immunized individual …”

Section: Discussionmentioning

confidence: 99%

“…In addition, using M3F5S‐IgM dispenses the use of an additional secondary antibody step to induce agglutination, as current human anti‐Vel sera contain mainly IgG antibodies. M3F5S‐IgM can therefore be used in an automated blood group analyzer, such as the Olympus PK7300, in contrasts to IgGs such as the previously described anti‐Vel IgG SpG213Dc …”

Section: Discussionmentioning

confidence: 99%

“…1 A Vel-specific antibody-producing human hybridoma cell line was recently described, which was also generated from an immunized individual. 17 Vel specificity of M3F5S-IgM was demonstrated by reactivity to SMIM1-expressing HEK293T cells and the TT TT 3+ † 3+ 2+ 2+ AG wt/wt TT TT 2+ 3+ 2+ 2+ AA wt/wt TT TT 2+ 2+ 2+ 2+ AA wt/A TT TT 2+ - 18 Interestingly, anti-Vel antibodies can activate complement, which forms an additional risk for alloimmunized patients due to possible intravascular hemolysis. 19 The recombinant M3F5S-IgM, with naturally occurring VH and VL, also showed complement activation.…”

Section: Discussionmentioning

confidence: 99%

“…M3F5S-IgM can therefore be used in an automated blood group analyzer, such as the Olympus PK7300, in contrasts to IgGs such as the previously described anti-Vel IgG SpG213Dc. 17 The Dutch National Screening Laboratory incorporated the use of M3F5S-IgM in their routine screening. The automated screening of more than 13,000 blood donations led to the identification of three Vel-negative blood donors.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Development of a recombinant anti‐Vel immunoglobulin M to identify Vel‐negative donors

Rijst

Lissenberg-Thunnissen

Ligthart

et al. 2019

Transfusion

View full text Add to dashboard Cite

BACKGROUND Alloimmunization against the high‐frequency Vel blood group antigen may result in transfusion reactions or hemolytic disease of fetus and newborn. Patients with anti‐Vel alloantibodies require Vel‐negative blood but Vel‐negative individuals are rare (1:4000). Identification of Vel‐negative donors ensures availability of Vel‐negative blood; however, accurate Vel blood group typing is difficult due to variable Vel antigen expression and limited availability of anti‐Vel typing sera. We report the production of a recombinant anti‐Vel that also identifies weak Vel expression. STUDY DESIGN AND METHODS A recombinant anti‐Vel monoclonal antibody was produced by cloning the variable regions from an anti‐Vel–specific B cell isolated from an alloimmunized patient into a vector harboring the constant regions of immunoglobulin (Ig)G1‐kappa or IgM‐kappa. Antibody Vel specificity was tested by reactivity to SMIM1‐transfected HEK293T cells and by testing various red blood cells (RBCs) of donors with normal, weak, or no Vel expression. High‐throughput donor screening applicability was tested using an automated blood group analyzer. RESULTS A Vel‐specific IgM class antibody was produced. The antibody was able to distinguish between Vel‐negative and very weak Vel antigen–expressing RBCs by direct agglutination and in high‐throughput settings using a fully automated blood group analyzer and performed better than currently used human anti‐Vel sera. High‐throughput screening of 13,288 blood donations identified three new Vel‐negative donors. CONCLUSION We generated a directly agglutinating recombinant anti‐Vel IgM, M3F5S‐IgM, functional in manual, automated agglutination assays and flow cytometry settings. This IgM anti‐Vel will improve diagnostics by facilitating the identification of Vel‐negative blood donors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Development of a recombinant anti‐Vel immunoglobulin M to identify Vel‐negative donors

Rijst

Lissenberg-Thunnissen

Ligthart

et al. 2019

Transfusion

View full text Add to dashboard Cite

show abstract

“…The classical serological method is not acceptable as a screening strategy for Vel− blood donors due to the scarcely available anti-Vel purified from Vel− individuals, which also displays heterogeneous levels of reactivity (Ballif et al, 2013;Cvejic et al, 2013;Storry et al, 2013;Haer-Wigman et al, 2015). However, monoclonal anti-Vel has recently been developed, side stepping this limitation (Danger et al, 2016).…”

Section: Dear Sirmentioning

confidence: 99%